Results Efficacy
* median SLEDAI dropped from 12 to 4 at week 12
* SRI-4 of 100% at week 12 (not other timepoints)
* at week 36 (last visit) SRI-4 still 70%, median SLEDAI still 4, 3 flares
Safety:
* 5/10 patients had IgG < 5g/l triggering IVIG repletion
* no severe AEs/infections occured
4/
Join us at Charité University and the IMPRS-IDI Graduate Program in Berlin to unravel NK cell clonality and memory! We are looking for motivated PhD candidates who are passionate about immunology. @romagnanilab.bsky.social
@timorckert.bsky.social
Apply now 👉 www.imprs-idi.org/home/
Our paper on the second Berlin patient came out in Nature today and I’m really happy we can share this story on World AIDS Day. I want to thank everyone on the team and all co-authors for their work over the years.
www.nature.com/articles/s41...
We are live
The @theisn.org launches a new journal
www.sciencedirect.com/journal/kidn...
www.youtube.com/watch?v=F2Pw...
I love the BBC Radio 1 Essential Mixes.
Our case report of a patient developing drug-induced systemic sclerosis after bleomycin exposure – still showing antibodies after 5 years. Nicely done Philipp 🎉 #rheumsky
authors.elsevier.com/sd/article/S...
Immunological Changes:
* Mature plasma cell depleted from peripheral blood
* CD38+ T cells vanish from the blood, but their clonal frequencies are unchanged > lose CD38, show reduced dysfunction-associated transcriptional profile
* NK cells are depleted, otherwise stable cell counts
5/
10 patients with refractory SLE (cSLEDAI > 3, failure of 2+ immunosuppressants) treated with 1800mg daratumumab (+dexamethasone for injection reaction prevention) 1/week for 8 weeks.
Primary EP: reduction in dsDNA antibodies at week 12
Secondary EP: clinical effect, safety, immunology
2/
Results – Primary Endpoint:
The primary endpoint (dsDNA antibody reduction at week 12) was met with a median dsDNA of 166.3 IU/ml at baseline to 61.1 IU/ml at week 12.
Vaccine-induced tetanus toxoid antibodies and total IgG were similarly reduced.
3/
Daratumumab in lupus 🦋 – results of our single-arm trial:
10 patients 8x daratumumab (1/week) at week 12:
☑️ reduced dsDNA antibodies
☑️ Median SLEDAI 12 > 4
☑️ SRI-4 at 12 weeks 100%
☑️ immunology improved*
out now at @nature.com Communications: www.nature.com/articles/s41...
#medsky #nephsky 🧪 1/
Looking for a #PhD project in #+immunology? The @romagnanilab.bsky.social offers two fully funded projects “Dissecting the Molecular Pathways of NK Cell Clonality” & “Dissecting the Molecular Pathways of NK Cell Memory“.
Apply by Dec 10 👉 www.mpiib-berlin.mpg.de/1947490/rese...
